The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300079249

Enrollment

Unknown

Registered

2023-12-28

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver enzyme function deterioration/ Abnormal liver function

Interventions

Pioglitazone (Control):Oral administration of pioglitazone 30 mg daily once for 6 months.

Metformin (Control):Oral administration of metformin 500 mg daily once for 6 months.

Ertugliflozin (Test drug):Oral administration of ertugliflozin 15 mg daily once for 6 months.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Participants for this randomize control trail must be Adult patients with age above 20 years and less than 70 years diagnosed with non alcoholic fatty liver diseases along with type 2 diabetes mellitus.

Exclusion criteria

Exclusion criteria: Participants not having non alcoholic fatty liver diseases along with type 2 diabetes mellitus, not willing to participate and the patient having elevated liver enzyme with any other risk factor such as hepatitis or other viral infection.

Design outcomes

Primary

Measure	Time frame
Improvement in liver function profile;	—

Secondary

Measure	Time frame
Improvement in Lipid profile;	—

Countries

Pakistan

Contacts

Public ContactHAROON BADSHAHH

DEPARTMENT OF PHARMACY ABDUL WALI KHAN UNIVERSITY MARDAN KYBERPAKHTUNKHWA

hbadshah@awkum.edu.pk+92 340 5840121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026